IMPROVEMENT OF THE ACTIVITY OF BACTERIOPHAGE PREPARATIONS DUE TO ADAPTATION TO CLINICAL STRAINS
The commercial bacteriophages-based preparation Pyo-bacteriophage composed of the phage lines active against purulent infections caused by Staphylococcus spp., Streptococccus spp., P. aeruginosa, P. mirabilis and E.coli. was developed by Felix d’Herelle in 1930. It has been manufactured and widely used in the FSU and post Soviet countries since then. According to the Soviet regulations the phage-based commercial preparations had to be regularly (minimum once per 6 months) checked for their activity and efficiency against the newly emerging strains provided from different geographical regions and clinics having various profiles. The current Georgian regulations for phage production were developed on the base of above mentioned Soviet approach.
The aim of the study was to check the efficiency of the existing commercial Pyo-bacteriophage against the urological E.coli strains circulating at the Tsulukidze Urology Center (Tbilisi, Georgia) and perform adaptation to these serovars with the purpose of using them in a recently started randomized, placebo-controlled, double-blind clinical trial.
During December 2014 and May 2016 in total 149 strains have been received from the TUC laboratory, among which were E.coli (35%), Enterococcus (29%), and Streptococcus sp. (21,5%) predominated, other species represented 13%. Over 100 clinical strains received from TUC prior to the start of the clinical trial were included in the adaptation cycles. Among 30 cultures recently obtained from the patients that are involved into the clinical trial 20 (67%) showed complete sensitivity while six (i.e. 20%) demonstrated intermediate susceptibility, four were resistant (13%) to the commercial Pyo-bacteriophage,
In conclusion, initial susceptibility of the clinical strains to the commercially available Pyo-bacteriophage was 43%, after seven adaptation cycles this index raised to 87% (including sensitive plus intermediate results). These results indicate on positive dynamics of phage activity achieved due to adaptation cycles and on importance of this procedure for improvement of the quality of phage-based preparations.
The aim of the study was to check the efficiency of the existing commercial Pyo-bacteriophage against the urological E.coli strains circulating at the Tsulukidze Urology Center (Tbilisi, Georgia) and perform adaptation to these serovars with the purpose of using them in a recently started randomized, placebo-controlled, double-blind clinical trial.
During December 2014 and May 2016 in total 149 strains have been received from the TUC laboratory, among which were E.coli (35%), Enterococcus (29%), and Streptococcus sp. (21,5%) predominated, other species represented 13%. Over 100 clinical strains received from TUC prior to the start of the clinical trial were included in the adaptation cycles. Among 30 cultures recently obtained from the patients that are involved into the clinical trial 20 (67%) showed complete sensitivity while six (i.e. 20%) demonstrated intermediate susceptibility, four were resistant (13%) to the commercial Pyo-bacteriophage,
In conclusion, initial susceptibility of the clinical strains to the commercially available Pyo-bacteriophage was 43%, after seven adaptation cycles this index raised to 87% (including sensitive plus intermediate results). These results indicate on positive dynamics of phage activity achieved due to adaptation cycles and on importance of this procedure for improvement of the quality of phage-based preparations.
Reference:
Poster Day 4-T12-Pos-07
Session:
Posters Covering the use of viruses to control infection and Processes governing the applied use of viruses
Presenters:
Nina Chanishvili
Session:
Day 4 Posters Covering: The use of viruses to control infection and Processes governing the applied use of viruses
Presentation type:
Poster presentation
Room:
Poster Halls
Date:
Thursday, 21 July 2016
Time:
12:05 - 15:30